Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aktis Oncology, Inc. (AKTS) since 2026 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aktis Oncology, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 2035832.
Total stock buying since 2026: $114,311,628.
Total stock sales since 2026: $2,870,659.
Total stock option exercises since 2026: $430,745.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 6,350,646 | $114,311,628 | 103,065 | $2,870,659 | 103,065 | $430,745 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2026-07 | 0 | $0 | 103,065 | $2,870,659 | 103,065 | $430,745 |
| 2026-01 | 6,350,646 | $114,311,628 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-07-17 | Herrmann Ken | Sale | 3,065 | 25.21 | 77,259 |
| 2026-07-17 | Herrmann Ken | Option Ex | 3,065 | .08 | 245 |
| 2026-07-08 | Czibere Akos (Chief Medical Officer) | Sale | 50,000 | 27.93 | 1,396,450 |
| 2026-07-08 | Czibere Akos (Chief Medical Officer) | Option Ex | 50,000 | 4.95 | 247,500 |
| 2026-07-08 | Ron-bigger Shulamit (Chief Operating Officer) | Sale | 50,000 | 27.94 | 1,396,950 |
| 2026-07-08 | Ron-bigger Shulamit (Chief Operating Officer) | Option Ex | 50,000 | 3.66 | 183,000 |
| 2026-01-12 | Oncology Impact Private Investment Fund 2, L.p. | Buy | 1,112,777 | 18.00 | 20,029,986 |
| 2026-01-12 | Mpm Oncology Innovations Fund Gp Llc | Buy | 1,112,777 | 18.00 | 20,029,986 |
| 2026-01-12 | Vida Ventures Ii-a, Llc | Buy | 835,000 | 18.00 | 15,030,000 |
| 2026-01-12 | Foley Todd | Buy | 232,870 | 18.00 | 4,191,660 |
| 2026-01-12 | Nodelman Oleg | Buy | 2,222,222 | 18.00 | 39,999,996 |
| 2026-01-12 | Kim Helen Susan | Buy | 835,000 | 18.00 | 15,030,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of AKTS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aktis Oncology, Inc. (symbol AKTS, CIK number 2035832) see the Securities and Exchange Commission (SEC) website.